CLOSING PANEL DISCUSSION: How sustainable drug development will empower and optimize the way clinical trials are planned to improve productivity and minimize costs

  • Future-proofing supply chains to endure greater long-term sustainability responsibilities
  • Adhering to sustainable practices without adding cost and risk to already tight budgets
  • Operational implications of striving for more sustainable trial design
  • Collaborating with supplier ecosystems to drive sustainability goals
  • Sharing best practice for circular supply chain strategies and creating win-win business opportunities

Chair: Joshua Cox, Vice President of Clinical Data & Analytics Capabilities, Eli Lilly and Company